Receptor News and Research

RSS

The surprising neurological benefits of GLP-1s

For people with chronic migraine, taking glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, for other conditions such as diabetes and weight loss, was associated with fewer emergency department visits and hospitalizations overall, and with less need for medications used to stop and prevent migraine attacks, according to a preliminary study released March 1, 2026, that will be presented at the American Academy of Neurology's 78th Annual Meeting taking place April 18-22, 2026, in Chicago and online.

2 Mar 2026

Common cardio drugs proven safe in myeloma patients

Commonly prescribed cardiovascular medications—such as statins, diuretics, and blood pressure drugs—appear to have little or no negative impact on survival among people living with multiple myeloma, according to new international research.

1 Mar 2026

Investigating microglia’s role in Alzheimer’s pathology

Announcing a new article publication for BIO Integration journal. Alzheimer's disease (AD) is a neurodegenerative disorder and the leading cause of dementia worldwide. Microglia, as central nervous system (CNS) resident macrophages, are key to AD pathology. Indeed, microglia aggregation around amyloid-β (Aβ) deposits is an AD hallmark.

1 Mar 2026

PEX38 protein offers new target against tropical trypanosome diseases

The pathogens that cause tropical diseases rely on an essential protein that is absent from all other organism. This discovery opens the possibility for targeted treatment.

27 Feb 2026

Protein partnership enhances innate immune sensing of viral RNA

Study reveals how two proteins cooperate in a key early step of antiviral detection, as reported by researchers at Science Tokyo.

27 Feb 2026

Mendelian randomization study reveals opposing roles for IL6 and IL6R in long-term mortality

A new research paper was published in Volume 18 of Aging-US on February 6, 2026, titled "Causal effects of inflammation on long-term mortality: a Mendelian randomization study."

27 Feb 2026

Researchers discover critical vulnerability shared by pathogens causing tropical diseases

Researchers working with Professor Ralf Erdmann at Ruhr University Bochum, Germany, have discovered a critical vulnerability shared by the pathogens that cause African sleeping sickness, Chagas disease, and leishmaniasis.

27 Feb 2026

Serial liquid biopsies reveal evolution in advanced prostate cancer

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that androgen receptor (AR) alterations consistently emerged and were linked to poorer outcomes across therapies.

26 Feb 2026

Ultra-sensitive CAR T cells target solid tumors

Though CAR T cells have been effective against certain blood cancers, they have not been for solid tumors.

26 Feb 2026

Combining healthy lifestyle and GLP-1 therapy reduces heart risks in diabetes

Individuals living with type 2 diabetes (T2D) had a significantly lower risk of poor cardiovascular health when they used a GLP-1 receptor agonist (GLP-1 RA) in combination with adhering to healthy lifestyle habits, according to a new study led by researchers at Harvard T.H. Chan School of Public Health and the Department of Veterans Affairs Boston Healthcare System.

25 Feb 2026

Could a rare gene variant help reduce smoking? New study suggests it might

An exome-wide association study of nearly 38,000 smokers from the Mexico City Prospective Study identified rare coding variants in CHRNB3 that are associated with substantially fewer cigarettes smoked per day. Cross-ancestry analyses in European and East Asian datasets support a role for the β3 nicotinic receptor subunit in modulating smoking intensity.

25 Feb 2026

Next-generation CAR T therapy offers hope but faces clinical challenges

A new editorial perspective was published in Volume 17 of Oncotarget on February 20, 2026, titled "CAR-T therapy: Trailblazing CAR(ing) in cancer treatment."

25 Feb 2026

Combined GLP-1 and GLP-2 treatment appears safe but does not beat placebo for obesity

In a 12-week randomized phase IIa trial in adults with obesity, the dual GLP-1/GLP-2 receptor agonist dapiglutide was well tolerated but did not achieve statistically significant weight loss compared with placebo at 4 mg or 6 mg doses. Although the higher dose showed modest within-group weight reduction and improved HbA1c, unexpectedly substantial placebo-associated weight loss limited the observed treatment effect.

24 Feb 2026

ATG14 found to be a critical defender against hepatic injury and fibrosis

Autophagy is indispensable for maintaining hepatocyte integrity, metabolic homeostasis, and survival. While several autophagy-related proteins have been studied in hepatic physiology, the specific role of Autophagy Related 14 (ATG14) in liver health has remained unclear.

24 Feb 2026

Ochsner MD Anderson Cancer Center delivers Louisiana’s first TIL therapy for melanoma

Ochsner MD Anderson Cancer Center at The Gayle and Tom Benson Cancer Center in New Orleans announces a milestone in advanced cancer treatment, as the first institution in Louisiana to provide an adult patient with tumor-infiltrating lymphocytes (TIL) therapy for advanced melanoma.

23 Feb 2026

Rytvela lowers inflammation and improves newborn survival in preclinical study

New research shows that Rytvela, an anti-inflammatory drug candidate, decreased premature birth and infant mortality when administered after the onset of preterm labor in a preclinical mouse model.

23 Feb 2026

Hormone-driven immune cells may explain sex differences in chronic pain

Chronic pain lasts longer for women than men, and new research suggests differences in hormone-regulated immune cells, called monocytes, may help explain why.

22 Feb 2026

Grant supports research into how microglia may spread toxic tau in Alzheimer’s

A researcher with the Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases at UT Health San Antonio has received a two-year, $402,500 grant award from the Cure Alzheimer's Fund to study how microglia, the brain's resident immune cells, paradoxically might contribute to the spread of toxic forms of tau protein in the disease.

20 Feb 2026

Distinct gut toxicity patterns emerge with targeted cancer treatments

A new paper was published in Volume 13 of Oncoscience on February 6, 2026, titled "Gastrointestinal toxicity of targeted cancer therapies in the United States: Clinicopathologic patterns, FDA safety frameworks, and implications for national patient protection."

20 Feb 2026

New technique synthesizes non-natural amino acids for advanced peptide therapeutics

Ozempic has been making headlines for its remarkable success in treating obesity and diabetes. Yet it is just one in a rapidly growing class of drugs called peptide therapeutics that sits between small molecules (like aspirin) and biologics (like antibodies).

20 Feb 2026